drugset
drugset / Trial / NCT01650090

Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma

NCT01650090 ↗

Phase 2 Completed 28 enrolled Eleison Pharmaceuticals LLC.
NaSingle-groupOpen-labelPrevention

Summary

To establish whether treatment with Inhaled Lipid Cisplatin (ILC) is effective in delaying/preventing pulmonary relapse in osteosarcoma patients in complete surgical remission following one or two prior pulmonary relapses.

Timeline

Start
2012-08
Primary completion
2018-11
Completion
2018-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 36 mg/m2 Inhaled

Indications

bone osteosarcoma